Zoetis Hits Historic Low P/E on OA Worry, But Pipeline Offers Hope

What happened

Zoetis shares have fallen to their lowest price-to-earnings ratio on record, driven by persistent controversy over the safety of its key osteoarthritis pain treatment Librela. Despite the setback, the company maintains a robust pipeline and solid long-term growth prospects, particularly in dermatology and parasiticides. The stock's decline reflects market concern that Librela's safety perception will structurally impair the OA franchise, with U.S. OA mAb revenue already down double digits. However, Zoetis's dominant position in animal health, 70%+ gross margins, and strong free cash flow provide a buffer against further downside. Near-term risk remains elevated pending Phase IV data and stabilization of OA sales, but the current valuation may offer an attractive entry for patient investors.

Implication

For the next 6-12 months, the path forward hinges on whether Librela safety concerns can be effectively managed through Phase IV data and veterinary education, which will determine if OA mAb revenue stabilizes. The stock's low P/E (around 20x trailing) already reflects a cautious outlook, but if growth disappoints further, multiples could compress to the high teens, implying downside toward $100. Conversely, a successful recovery in OA adoption could drive a re-rating to 23-24x EPS, supporting mid-teens total returns from current levels. The dividend growth slowdown from 16% to 6% signals management's pragmatic view of future cash flows, reducing the appeal of the 'compounder' narrative. Therefore, a disciplined approach is to accumulate only if the stock dips toward the $110 attractive entry or if evidence of OA mAb recovery emerges.

Thesis delta

The market narrative has shifted from viewing Zoetis as a high-growth compounder to a mature grower with temporary headwinds, as evidenced by the historic low P/E. The master report's WAIT rating remains appropriate, as the stock's valuation now prices in a bear case but lacks the catalyst for near-term upside. Investors should require a sharper discount (below $110) or concrete proof of OA mAb turnaround before committing capital.